News | Cardiovascular Surgery | December 11, 2018

Transplanting Pig Hearts Into Humans One Step Closer

Professor Stig Steen’s heart preservation technology shows success in transplanting hearts from pigs to baboons

Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.


December 11, 2018 — The scientific journal Nature recently published an article from Munich University Hospital which describes the long-term survival of baboons that had received a heart transplant from genetically modified pigs.1 This is an important step forward on the way to being able to give humans porcine heart transplants.

Pig hearts are very similar in size, anatomy and function to human hearts, so are used to train medical students. Porcine hearts are the gold-standard in pre-clinical animal testing for all cardiovascular devices prior to use in humans to both test the safety and efficacy, and refine the implant procedures.

The article describes two requirements that have enabled the good results. One of these requirements is the introduction of non-ischemic heart preservation in accordance with the method using the products developed by Prof. Stig Steen and Swedish company XVIVO, and the other requirement is inhibition of post-transplantation growth of the heart, which otherwise would become too big for the primate.

XVIVO owns all commercial rights to the technology and is submitting an application to the Swedish Medical Products Agency as a prerequisite for a multicenter study on XVIVO’s products for heart preservation. The company plans to submit the application within approximately one month.

The XVIVO products consist of a preservation solution which has the same composition as that clinically used in the heart transplant study ongoing at the University Hospitals of Lund, earlier pre-clinical studies and now pre-clinically used in Munich for heart preservation in xenotransplantation. The technology also includes a portable heart preservation machine incorporating a single-use component which has been constructed by XVIVO, in accordance with Steen’s technology.

According to the United Network for Organ Sharing (UNOS), a total of 3,133 heart transplants have occurred in 2018, while 3,832 patients are currently waiting for a new heart,2 highlighting the need for creative solutions. An average of 20 people die every day while waiting for an organ transplant.2

For more information: www.xvivoperfusion.com

First Human Receives a Pig Heart Transplant  using this technology (Jan. 7, 2022)
 

Reference

1. Längin M., Mayr T., Reichart B., et al. Consistent success in life-supporting porcine cardiac xenotransplantation. Nature, published online Dec. 5, 2018. https://doi.org/10.1038/s41586-018-0765-z. Accessed Dec. 11, 2018.

2. https://unos.org/data/. Accessed Dec. 11, 2018.


Related Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
Subscribe Now